FDA approves Merck’s oral PCSK9 inhibitor Lipfendra, but cardiologists question its immediate impact

The FDA has granted approval to enlicitide, marketed by Merck as Lipfendra, marking the first oral PCSK9 inhibitor for lowering blood cholesterol.

The drug arrives as new clinical guidelines encourage more aggressive cholesterol reduction, positioning it as a potentially valuable option for patients with established or high risk of cardiovascular disease.

Despite the scientific milestone, preventive cardiologist Vishal Khetpal cautions that prescribing patterns may not shift right away and he remains unsure whether the medication will prove to be a game‑changer in everyday practice.

Khetpal’s commentary underscores broader questions about how such innovations fit into current prevention strategies and their real‑world impact on patient care.